RecruitingNCT02806388
Individualized Molecular Profiling for Allocation to Clinical Trials (IMPACT) Project
Sponsor
National Cancer Centre, Singapore
Enrollment
5,500 participants
Start Date
Oct 1, 2011
Study Type
OBSERVATIONAL
Conditions
Summary
This study aims to screen tumor molecular profile for better selection of anticancer treatment, in particular, allocation to clinical trials if available.
Eligibility
Min Age: 12 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a new treatment for people with solid tumor. The study is currently recruiting participants at 1 location. People eligible for this study include aged 12 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02806388
Related Trials
Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid Tumors
NCT065633751 location
NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors
NCT074893781 location
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
NCT063984181 location
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
NCT0710972615 locations
Dabrafenib and/or Trametinib Rollover Study
NCT0334050632 locations